The relationship between clonal heterogeneity of tumor cells with TP53 somatic mutations across the bulk tumor sample and tumor immune status suggests that tumors with a more homogenous population of cancer cells, have less overall mutations, and are also more immune‐poor. Here, TP53 is linked to neoplasm.